HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of penehyclidine for prevention of post operative nausea and vomitting in patients undergoing total thyroidectomy under total intravenous anaesthesia with propofol-remifentanil.

AbstractBACKGROUD:
Postoperative nausea and vomiting (PONV) is one of the most common complications after total thyroidectomy under general anesthesia. Total intravenous anesthesia (TIVA) has been documented to prevent PONV in patients undergoing total thyroidectomy. Penehyclidine, an anticholinergic agent with an elimination half-life of over 10 h, is widely used as premedication to reduce glandular secretion. This study aimed to explore the preventative effects of penehyclidine with propofol-remifentanil-TIVA to single-TIVA on PONV in patients undergoing total thyroidectomy.
METHODS:
A total of 100 patients scheduled for total thyroidectomy were randomly assigned to either the penehyclidine group (n = 50) or TIVA group (n = 50). Propofol and remifentanil were was used for TIVA in all patients. No patients who received premedication. Patients were administrated with either 5 ml of normal saline or 0.5 mg of penehyclidine soon after anesthesia induction. The incidence of nausea and vomiting, the severity of nausea, the requirement of rescue antiemetics, and adverse effects were investigated during the first 24 h in two time periods (0-2 h and 2-24 h).
RESULTS:
The overall PONV incidence during the 24 h after surgery was significantly lower in the penehyclidine group compared with the TIVA group (12% vs 36%, P < 0.005). Besides, the incidence of nausea and the incidence of vomiting were significantly lower in the penehyclidine group compared with the TIVA group at 2-24 h after surgery. However, there was no significant difference between the two groups at 0-2 h after surgery.
CONCLUSIONS:
Administration of penehyclidine under TIVA with propofol-remifentanil is more effective for prevention of PONV than TIVA alone, especially 2-24 h after total thyroidectomy.
TRIAL REGISTRATION:
https://www.chictr.org.cn/edit.aspx?pid=132463&htm=4 (Ref: ChiCTR2100050278, the full date of first registration: 25/08/2021).
AuthorsTing Lu, Rongrong Li, Jiacheng Sun, Jing Chen
JournalBMC anesthesiology (BMC Anesthesiol) Vol. 22 Issue 1 Pg. 317 (10 14 2022) ISSN: 1471-2253 [Electronic] England
PMID36241968 (Publication Type: Journal Article, Randomized Controlled Trial)
Copyright© 2022. The Author(s).
Chemical References
  • Anesthetics, Intravenous
  • Antiemetics
  • Cholinergic Antagonists
  • Piperidines
  • Quinuclidines
  • Saline Solution
  • penehyclidine
  • Remifentanil
  • Propofol
Topics
  • Anesthesia, General (adverse effects)
  • Anesthesia, Intravenous
  • Anesthetics, Intravenous (adverse effects)
  • Antiemetics (therapeutic use)
  • Cholinergic Antagonists
  • Humans
  • Piperidines (adverse effects)
  • Postoperative Nausea and Vomiting (chemically induced, epidemiology, prevention & control)
  • Propofol (adverse effects)
  • Quinuclidines
  • Remifentanil
  • Saline Solution
  • Thyroidectomy (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: